

Jason A Tye-Din

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287122/publications.pdf>

Version: 2024-02-01

75
papers

3,488
citations

147801

31
h-index

144013

57
g-index

76
all docs

76
docs citations

76
times ranked

3459
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal assessment of the common sense model before and during the COVID-19 pandemic: A large coeliac disease cohort study. <i>Journal of Psychosomatic Research</i> , 2022, 153, 110711.	2.6	3
2	The mosaic oat genome gives insights into a uniquely healthy cereal crop. <i>Nature</i> , 2022, 606, 113-119.	27.8	70
3	Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease—time to ditch the “gluten” from “non-coeliac gluten sensitivity”. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 340-341.		0
4	Review article: Follow-up of coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, .	3.7	2
5	Iron deficiency. <i>Lancet</i> , The, 2021, 397, 233-248.	13.7	396
6	Current and emerging therapies for coeliac disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 181-195.	17.8	63
7	The Risk of Contracting COVID-19 Is Not Increased in Patients With Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 391-393.	4.4	38
8	Risk perception and knowledge of COVID-19 in patients with celiac disease. <i>World Journal of Gastroenterology</i> , 2021, 27, 1213-1225.	3.3	8
9	A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. <i>Frontiers in Immunology</i> , 2021, 12, 661622.	4.8	14
10	Systematic review: Exploration of the impact of psychosocial factors on quality of life in adults living with coeliac disease. <i>Journal of Psychosomatic Research</i> , 2021, 147, 110537.	2.6	10
11	Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease. <i>Clinical and Experimental Immunology</i> , 2021, 204, 321-334.	2.6	15
12	Quality of life in coeliac disease: relationship between psychosocial processes and quality of life in a sample of 1697 adults living with coeliac disease. <i>Journal of Psychosomatic Research</i> , 2021, 151, 110652.	2.6	10
13	Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells. <i>IScience</i> , 2021, 24, 103509.	4.1	10
14	Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity. <i>United European Gastroenterology Journal</i> , 2020, 8, 108-118.	3.8	26
15	Characterisation of clinical and immune reactivity to barley and rye ingestion in children with coeliac disease. <i>Gut</i> , 2020, 69, 830-840.	12.1	10
16	T cell receptor cross-reactivity between gliadin and bacterial peptides in celiac disease. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 49-61.	8.2	91
17	Update 2020: nomenclature and listing of celiac disease—relevant gluten epitopes recognized by CD4+ T cells. <i>Immunogenetics</i> , 2020, 72, 85-88.	2.4	125
18	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 244-252.	3.7	27

#	ARTICLE	IF	CITATIONS
19	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. BMC Medicine, 2020, 18, 362.	5.5	22
20	Circulating gluten-specific, but not CMV-specific, CD39 + regulatory T cells have an oligoclonal TCR repertoire. Clinical and Translational Immunology, 2020, 9, e1096.	3.8	7
21	Editorial: inaccuracies in attribution of symptoms due to gluten not just in those with self-reported noncoeliac gluten sensitivity. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 403-404.	3.7	1
22	Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 901-910.	3.7	51
23	Preparation and Characterization of Avenin-Enriched Oat Protein by Chill Precipitation for Feeding Trials in Celiac Disease. Frontiers in Nutrition, 2019, 6, 162.	3.7	15
24	Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. Science Advances, 2019, 5, eaaw7756.	10.3	84
25	824 " Acute Gluten-Induced Symptoms in Celiac Disease (CED) are Quantitatively Correlated with Serum Cytokine Response. Gastroenterology, 2019, 156, S-177.	1.3	0
26	Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease. Clinical and Experimental Immunology, 2019, 199, 68-78.	2.6	36
27	Maintenance of a gluten free diet in coeliac disease: The roles of self-regulation, habit, psychological resources, motivation, support, and goal priority. Appetite, 2018, 125, 356-366.	3.7	32
28	Rapid, Loop-Mediated Isothermal Amplification Detection of Celiac Disease Risk Alleles. Journal of Molecular Diagnostics, 2018, 20, 307-315.	2.8	3
29	Resolving incomplete single nucleotide polymorphism tagging of HLA-DQ2.2 for coeliac disease genotyping using digital droplet PCR. Hla, 2018, 91, 280-288.	0.6	1
30	Gluten in "co-gluten-free" manufactured foods in Australia: a cross-sectional study. Medical Journal of Australia, 2018, 209, 448-449.	1.7	8
31	Celiac Disease: A Review of Current Concepts in Pathogenesis, Prevention, and Novel Therapies. Frontiers in Pediatrics, 2018, 6, 350.	1.9	111
32	High rates of variation in HLA-DQ2/DQ8 testing for coeliac disease: results from an RCPAQAP pilot program. Journal of Clinical Pathology, 2018, 71, 900-905.	2.0	4
33	Gluten in "co-gluten-free" food from food outlets in Melbourne: a cross-sectional study. Medical Journal of Australia, 2018, 209, 42-43.	1.7	17
34	T cells in coeliac disease: a rational target for diagnosis and therapy. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 583-584.	17.8	9
35	Food knowledge and psychological state predict adherence to a gluten-free diet in a survey of 5310 Australians and New Zealanders with coeliac disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 78-86.	3.7	50
36	Genome mapping of seed-borne allergens and immunoresponsive proteins in wheat. Science Advances, 2018, 4, eaar8602.	10.3	130

#	ARTICLE	IF	CITATIONS
37	Interpreting tests for coeliac disease: Tips, pitfalls and updates. , 2018, 47, 28-33.		7
38	Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. <i>Psychology, Health and Medicine</i> , 2017, 22, 524-534.	2.4	43
39	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 479-493.	8.1	113
40	Circulating gluten-specific FOXP3 + CD39 + regulatory T cells have impaired suppressive function in patients with celiac disease. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1592-1603.e8.	2.9	63
41	The practice and perception of precautionary allergen labelling by the Australasian food manufacturing industry. <i>Clinical and Experimental Allergy</i> , 2017, 47, 961-968.	2.9	5
42	Editorial: a novel approach to monitor mucosal healing in coeliac disease—“as simple as shifting goalposts?”. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 894-895.	3.7	1
43	Serum IL-2 and IL-8 are Elevated within 4 h after Gluten Ingestion in Celiac Disease (CED) Patients on Gluten-Free Diet (GFD) and Potential to Resolve Indeterminate Diagnoses for Patients on GFD. <i>Gastroenterology</i> , 2017, 152, S114.	1.3	1
44	Discrepancies in genetic testing results for coeliac disease: call for standardised testing and reporting. <i>Medical Journal of Australia</i> , 2017, 207, 179-180.	1.7	1
45	Duodenal Bacteria From Patients With Celiac Disease and Healthy Subjects Distinctly Affect Gluten Breakdown and Immunogenicity. <i>Gastroenterology</i> , 2016, 151, 670-683.	1.3	177
46	Coeliac disease: a unique model for investigating broken tolerance in autoimmunity. <i>Clinical and Translational Immunology</i> , 2016, 5, e112.	3.8	37
47	846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S180.	1.3	2
48	Sa1396 A Single Intradermal (ID) Injection of Nexvax2®, a Peptide Composition With Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People With Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S304.	1.3	4
49	Sa1398 Immunogenic Gluten Is Modulated by Small Intestinal Bacterial Hydrolysis. <i>Gastroenterology</i> , 2016, 150, S304.	1.3	0
50	Sa1395 Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S304.	1.3	2
51	Reply. <i>Gastroenterology</i> , 2016, 150, 779-780.	1.3	0
52	Genomic prediction of celiac disease targeting HLA-positive individuals. <i>Genome Medicine</i> , 2015, 7, 72.	8.2	25
53	Consistency in Polyclonal T-cell Responses to Gluten Between Children and Adults With Celiac Disease. <i>Gastroenterology</i> , 2015, 149, 1541-1552.e2.	1.3	46
54	Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an Australasian perspective. <i>Internal Medicine Journal</i> , 2015, 45, 441-450.	0.8	40

#	ARTICLE	IF	CITATIONS
55	Ingestion of oats and barley in patients with celiac disease mobilizes cross-reactive T cells activated by avenin peptides and immuno-dominant hordein peptides. <i>Journal of Autoimmunity</i> , 2015, 56, 56-65.	6.5	62
56	Point-of-care testing for coeliac disease antibodies – what is the evidence?. <i>Medical Journal of Australia</i> , 2015, 202, 418-419.	1.7	2
57	Accurate and Robust Genomic Prediction of Celiac Disease Using Statistical Learning. <i>PLoS Genetics</i> , 2014, 10, e1004137.	3.5	95
58	Ex-vivo whole blood secretion of interferon (IFN)- γ and IFN- γ -inducible protein-10 measured by enzyme-linked immunosorbent assay are as sensitive as IFN- γ enzyme-linked immunospot for the detection of gluten-reactive T cells in human leucocyte antigen (HLA)-DQ2.5-associated coeliac disease. <i>Clinical and Experimental Immunology</i> , 2014, 175, 305-315.	2.6	50
59	A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways. <i>BMC Medicine</i> , 2013, 11, 188.	5.5	88
60	Biased T Cell Receptor Usage Directed against Human Leukocyte Antigen DQ8-Restricted Gliadin Peptides Is Associated with Celiac Disease. <i>Immunity</i> , 2012, 37, 611-621.	14.3	121
61	Sa1317 A Whole Blood Cytokine Release Assay Employing Short-Term Gluten Challenge Identifies Patients With Celiac Disease on a Gluten Free Diet. <i>Gastroenterology</i> , 2012, 142, S-271.	1.3	0
62	For Celiac Disease, Diagnosis Is Not Enough. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 900-901.	4.4	11
63	A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 [®] in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet. <i>Gastroenterology</i> , 2011, 140, S-437-S-438.	1.3	31
64	A Population Study to Optimize the Role of Serology and Genetics in the Diagnosis of Celiac Disease (CD). <i>Gastroenterology</i> , 2011, 140, S-440.	1.3	0
65	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. <i>Clinical Immunology</i> , 2010, 134, 289-295.	3.2	125
66	Surveillance of FAP: a prospective blinded comparison of capsule endoscopy and other GI imaging to detect small bowel polyps. <i>Hereditary Cancer in Clinical Practice</i> , 2010, 8, 3.	1.5	34
67	Dissecting the cell response to hordeins in coeliac disease can develop barley with reduced immunotoxicity. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1184-1191.	3.7	28
68	Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease. <i>Science Translational Medicine</i> , 2010, 2, 41ra51.	12.4	393
69	354 Dominance, Hierarchy and Redundancy of T Cell Stimulatory Peptides in Celiac Disease. <i>Gastroenterology</i> , 2009, 136, A-57.	1.3	0
70	Immunopathogenesis of celiac disease. <i>Current Gastroenterology Reports</i> , 2008, 10, 458-465.	2.5	33
71	A Structural and Immunological Basis for the Role of Human Leukocyte Antigen DQ8 in Celiac Disease. <i>Immunity</i> , 2007, 27, 23-34.	14.3	157
72	Aspiration in the Context of Upper Gastrointestinal Endoscopy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 223-225.	1.7	9

#	ARTICLE	IF	CITATIONS
73	Antagonists and non-toxic variants of the dominant wheat gliadin T cell epitope in coeliac disease. Gut, 2006, 55, 485-491.	12.1	56
74	A systematic approach for comprehensive T-cell epitope discovery using peptide libraries. Bioinformatics, 2005, 21, i29-i37.	4.1	17
75	T cells in peripheral blood after gluten challenge in coeliac disease. Gut, 2005, 54, 1217-1223.	12.1	110